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A B S T R A C T 
The problem of hyperprolactinaemia is a relatively new and the information regarding it is still controversial. 
The aim of the present investigation is to analyze a five-year experience of the Clinic of Endocrinology and 
Metabolic Diseases, Prof. Paraskev Stoyanov Medical University of Varna in this field. Eighty-six patients 
with high prolactin levels are analyzed: 81 females at a mean age of 32.4 years and 5 males at a mean age of 
37.3 years. The patients are grouped as follows: 25 with prolactinomas, 23 with hypothalamic 
hyperprolactinaemia, 14 with empty sella syndrome, 6 with another hormone-secreting pituitary tumor, 4 
with primary hypothyroidism and 5 with drug-induced hyperprolactinaemia. The diagnosis is based on clini-
cal features, hormone levels, computer assisted tomography and magnetic resonance imaging. The main prin-
ciples of treatment, their side effects and the results are discussed. 
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I N T R O D U C T I O N 
Hyperprolactinaemia is among the most common distur-
bances in hypothalamo-pituitary axis function. It occurs 
more frequently in females than in males. The incidence of 
hyperprolactinaemias in general population is found to be 
approximately 0.4%, whereas in female patients with re-
productive problems it reaches 9-17%. 
Hyperprolactinaemia comprises a heterogeneous group of 
disturbances characterized by high serum prolactin levels 
with or without hypogonadism and galactorhoea. 
There are three main reasons known and used in the every-
day clinical practice - physiological, pharmacological and 
pathological hyperprolactinaemia. Most often, the diagnos-
tic and therapeutic interest is directed toward the third group 
which includes prolactinomas (incidence of 11 -23% in the 
general population) followed by hypothalamic hyper-
prolactinaemia and some other pituitary diseases 
(acromegaly, Cushing disease, empty sella syndrome, etc.), 
thyroid gland pathology and some other nonendocrine dis-
eases (5). 
The treatment of hyperprolactinaemias is a very disputable 
problem and depends on the aims o f the team of physi-
cian-patient and the ratio between the expected success and 
the potential risk of the chosen therapeutic option (4). 
Address for correspondence: 
K. Hristozov, Clin, of Endocrinology' and Metabolic Diseases. Prof. 
P. Stoyanov Medica! University of Varna. 55 Marin Drinov St. 
BG-9002 Varna. BULGARIA 
E-mail: microeffecta^nat.bg 
The correctly chosen and well-conducted treatment should 
normalize the hormone hypersecretion, shrink the tumor 
size and correct the optic and other cranial nerve distur-
bances. I f other parts o f the hypothalamo-pituitary axis are 
also damaged by the primary process they should be nor-
malized and, i f possible, the need for chronic hor-
mone-replacement therapy has to be prevented (8) . With 
the introduction in the clinical practice o f new very potent 
dopamin agonists the pharmacotherapy o f hyperpr-
olactinaemias became a very serious alternative of the neu-
rosurgery and radiotherapy. 
M A T E R I A L AND M E T H O D S 
For the period 1995-2001, 86 patients with hyperprolactin-
aemia are diagnosed, treated and followed-up in the Clinic 
of Endocrinology and Metabolic Diseases, Prof. Paraskev 
Stoyanov Medical University of Varna. O f them, 81 are fe-
males, aged between 17 and 56 years (mean age of 32.4 
years) and 5 are males, aged between 23 and 60 years 
(mean age of 37.3 years). Prolactin serum levels are deter-
mined in all patients using immunoenzyme method with an 
upper limit o f the normal range of 26ng/ml for females and 
of 18ng/ml for males. In addition, profile X-ray o f the scull, 
computer assisted tomography ( C T ) and, in some cases, 
magnetic resonance imaging ( M R I ) o f the brain and pitu-
itary gland are done, visual fields and vision status are 
checked. Control serum levels of prolactin are measured 
annually and in cases where prolactinomas are present an-
nual C T o f the hypophysis is also performed. 
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R E S U L T S AND D I S C U S S I O N 
In our cases the clinical signs suggesting hyperprolactin­
aemia are as follows: galactorhoea in 71 patients (83%), 
hypogonadism in 48 (56%), headache in 23 (27%), and v i ­
sual disturbances (bilateral hemianopsy) in 2 cases (2.3%). 
Patients' distribution depending on the reason for 
hyperprolactinaemia is the following (Fig. 1): 25 with 
prolactinomas, 23 with hypothalamic hyperprolactinaemia, 
14 with empty sella syndrome, 6 with another hor­
mone-secreting pituitary tumor, 4 with primary 




4.5% 3<>/0 4 o / o 
(~J prolactinoma 
3 hypothalamic 
Щ empty sella syndrome 
Щ primary hypothyroidism 
Q Cushing disease 
0 acromegaly 
| drug-induced 
Fig. 1. Etiology of hyperprolactinaemia 
From all patients with proved prolactinoma (N=23) in 8 
cases macroadenoma is found (2 male and 6 female) and in 
15 cases all o f which are women microadenoma is found. 
The mean level o f serum prolactin is 98 ±4.5ng/ml. In 7 pa­
tients with prolactinoma an operation was performed, two 
remain just under control without further treatment and in 
14 cases a treatment with dopamin agonist (Bromocriptin 
o f 2.5-10.Omg/d) was introduced. Since the therapeutic ef­
fect was insufficient and the side effects o f Bromocriptin 
were pronounced in four of these cases Bromocriptin was 
replaced by Cabergoline (Dostinex) in an average dose of 
Э.5-1 .Omg/week. The patients with low prolactin levels 
25-40ng/ml) remain just under control, 
n the group of macroadenoma patients (2 males and 2 fe-
nales) an operation was performed - in 3 cases cranial 
idenomectomy and in one case transsphenoidal aden-
tmectomy. In 3 patients with microadenoma transsphen-
lidal adenomectomy was done, too. After the operation 
omplete radicalism was achieved in 2 patients, in 3 there 
/as residual prolactin secretion, in one case residual tissue 
lus increased prolactin secretion and one case relapse of 
te tumor occurred. The ophthalmologic correction o f the 
reoperatively registered bitemporal hemianopsy was 
:hieved in 3 patients. During the first year of follow-up in 
16 (71 % ) of all the patients with prolactinoma hormonal re­
mission was achieved, in 6 cases (31%) there was a tumor 
shrinkage and in 6 5 % of the patients with proved 
hypogonadism the gonadal function nonnalized (including 
3 pregnancies). 
A s a reason for hyperprolactinaemia in 23 women hypotha­
lamic dysfunction was found. This diagnosis was based on 
exclusion of any physiologic, pharmacologic or organic 
reason for high prolactin levels. In 14 cases (70%) 
hyperprolactinaemia was associated with gonadal dysfunc­
tion, in 7 of them with ovarian polycystosis. The serum lev­
els o f prolactin in all patients did not exceed 40ng/ml. A 
treatment with Bromocriptin was introduced in all patients 
from this group and in 20 cases (90%) hormonal levels 
were nonnalized, whereas gonadal function was restored in 
only 12 patients. 
In 14 cases as a reason for high prolactin levels empty sella 
syndrome was found on C T of the pituitary gland. The 
mean levels o f prolactin were of 51 +2.3ng/ml. Brom­
ocriptin in a dose of 2.5-7.5mg/d normalized hormonal lev­
els in 9 cases and gonadal function in 7 ones. 
In 6 patients hyperprolactinaemia was found to be due to 
other pituitary tumors (4 cases with STH-producing 
adenomas and 2 with Cushing disease). In 2 of acromegalic 
patients hyperprolactinaemia was caused by cosecretion of 
prolactin and S T H , whereas in the rest patients postopera­
tive monosecretion of prolactin was found to be the reason. 
In ACTH-producing adenomas hyperprolactinaemia was 
diagnosed during the active phase of the disease. The intro­
duced treatment with dopamin agonist achieved hormonal 
remission in all patients of the group and normalized the 
gonadal function in 3 of them. 
in 4 patients with primary hypothyroidism ( T S H 58.9 
±4.5mU/l; F T 4 0.41.41 ±0.12ng/ml) caused by autoim­
mune thyroiditis the mean levels of prolactin were 69 
±3.4ng/ml. Clinically, in 2 of them there was a galactorhoea 
and hypogonadism. The levels of prolactin reduced, 
galactorhoea disappeared and hypogonadism was corrected 
when replacement therapy with levothyroxin was adminis­
tered. 
Drug-induced hyperprolactinaemia was found in 5 patients 
caused by fvletoclopramide (2 cases), Dopegyt (1) , 
Verapamil (1) and psychotropic drugs (1). The therapy with 
these drugs was interrupted afterward prolactin levels de­
creased. Only in one case (on a psychotropic drug) 
Bromocriptin was introduced simultaneously with the other 
medication afterward prolactin also nonnalized its levels. 
Hyperprolactinaemia is one of the most common distur­
bances in the function of anterior hypophysis which leads to 
series o f endocrine (infertility, osteoporosis) and 
neuroophthalmologic problems (5) . 
The most common clinical sign is galactorhoea which fre­
quency is almost 80% in women with hyperprolactinaemia, 
whereas hyperprolactinaemia could be found in only about 
50% in women with galactorhoea (1). 
Our therapeutic aims in this series o f patients were normal­
ization of hormone secretion and, in the presence o f 
Hyperprolactinaemia - etiology, diagnosis and treatment 
prolactinoma, tumor shrinkage and neuroophthalmologic 
correction. We also aimed at restoring the disturbed go­
nadal function and preventing, i f possible, the need o f per­
manent hormone replacement therapy. The treatment 
choice in the presence of prolactinoma depends on the tu­
mor size and the serum level of prolactin. A n operation was 
perfonned in 7 out o f 23 patients with prolactinoma using 
the transsphenoidal approach in 3 patients with micro­
adenoma and in one patient with macroadenoma but with­
out suprasellar extension. In the other 14 cases the therapy 
was only conservative with dopamin agonists and in 12 pa­
tients the prolactin level restored to normal range as well as 
in 9 patients the tumor shrinkage was achieved. The reasons 
in some patients to perform an operation are various: not 
tolerated side effects o f dopamin agonists such as 
hypotension, gastro-intestinal discomfort; the increase of 
prolactin secretion after stopping the drugs and in some 
cases financial problems. This was the case in 5 of our pa­
tients. 
Unfortunately, despite the good results from the operative 
treatment it is not definitive sometimes. We found out that 
the normal prolactin levels immediately or soon after the 
operation do not testify always for definitive healing. Only 
in 2 out o f 7 operated patients the prolactin level remained 
normal during the 2-year follow-up period. In the other 5 
cases the operation was followed by treatment with 
Bromocriptin. In 2 cases residual tumor tissue was found 
out as a reason and in 3 cases an interruption of 
hypothalamo-pituitary connection could be discussed (9). 
The other problem that could be discussed is about women 
with microprolactinomas, moderate hyperprolactinaemia 
without gonadal disturbances and galactorhoea. In most 
cases, microadenomas do not progress to macroadenomas 
because of their lower proliferative potential (7). That was 
also confirmed in our series o f patients and in these cases 
we used to check the prolactin level every 6 months to­
gether with annual C T of the hypophysis. 
The results from the surgical treatment of macroadenomas 
are not very promising. The effect from transsphenoidal op­
eration of these tumors reaches hardly 30% and because of 
this there is a need for lifelong treatment with dopamin 
agonists (6). 
Furthermore, the patients with macro- adenomas have 
greater risk for development of hypopituitarism due to 
intraoperative trauma or compression o f the normal pitu­
itary tissue by the tumor. 
Hypothalamic hyperprolactinaemia ( H H ) called also idio­
pathic, functional or secondary is of great interest in the 
clinical practice. This is a diagnosis o f exclusion, which re­
quires a broad spectrum of laboratory and instrumental 
methods for exclusion of any other reason. Various factors 
could be discussed in H H etiopathogenesis such as distur­
bances in synthesis or secretion of dopamin from 
dorsomedial nucleus of hypothalamus (3), defects in secre­
tion of other neurotransmitters such as G A B A , 
cholecystokinin, V I P (10). 
The patients with hypothalamic hyperprolactinaemia have 
lower mean prolactin levels in comparison to 
prolactinomas. The secretion of prolactin in case of H H is 
not autonomous and we could suppose that regulatory links 
between prolactin stimulating and inhibiting factors, on one 
hand, and lactotrophic cells in hypophysis, on the other 
hand, are relatively more intact in comparison to 
prolactinomas. 
There is neither consensus, nor therapeutic algorithm con­
cerning the indications for stalling therapy with dopamin 
agonists in H H . Some publications state that i f functional 
hyperprolactinaemia is not complicated with gonadal dys­
function and/or galactorhoea it does not require active treat­
ment but only periodic control of prolactin levels. We con­
ducted active treatment in 20 out of 23 patients with H H . 
Hormonal remission was achieved in all o f them and in 12 
the gonadal function was normalized. 
The so-called empty sella syndrome commonly occurring 
in endocrinological practice does not exclude the coexis­
tence of micro- or macroprolactinoma (2). In our patients 
we could succeed to control hyperprolactinaemia and tu­
mor size by dopamin agonist administration. 
In acromegalic patients galactorhoea with or without 
hyperprolactinaemia could result from co-secretion of S T H 
and prolactin, lactotrophic effect o f S T H or interruption of 
pituitary stalk by the tumor (2). In such a case we controlled 
the high prolactin levels by dopamin agonists. 
C O N C L U S I O N S 
1. Women in reproductive age with microprolactinomas 
should be treated with dopamin agonists when a 
pregnancy is planned or they are in amenorhoea. 
2. The surgical therapy (transsphenoidal adenomectomy) 
should be the treatment of choice when dopamin 
agonists' effect is not satisfactory or the side effects 
could not be tolerated. 
3. In most cases hypothalamic hyperprolactinaemia does 
not require active treatment with dopamin agonists. 
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